Lilly's Cyramza OK'd for US lung cancer patients
This article was originally published in Scrip
Executive Summary
The FDA on 12 December granted Lilly a third indication this year for Cyramza (ramucirumab) – this time as a treatment for patients with metastatic non-small-cell lung cancer (NSCLC), the most common form of lung cancer.